KUALA LUMPUR, July 29 (Bernama) -- Sanofi has delivered solid growth in Q2 2019 driven by Sanofi Genzyme, Sanofi Pasteur and Emerging Markets with net sales of €8,628 million, an increase of 5.5 per cent on a reported basis. (€1 = RM4.59)
The company has reported that Sanofi Genzyme sales were up 21.8 per cent due to the strong launch performance of Dupixent®, while vaccine sales increased 24.7 per cent, mainly reflecting the recovery and growth of Pentaxim® in China and low basis for comparison.
Its business net income in the same quarter also recorded an increase of 5.3 per cent to €1,641 million, according to a statement.
“Our increased focus in R&D delivered important results with several positive data read-outs and the achievement of regulatory milestones,” said Sanofi chief executive officer, Olivier Brandicourt.
No comments:
Post a Comment